NZ599480A - Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof - Google Patents

Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof

Info

Publication number
NZ599480A
NZ599480A NZ599480A NZ59948008A NZ599480A NZ 599480 A NZ599480 A NZ 599480A NZ 599480 A NZ599480 A NZ 599480A NZ 59948008 A NZ59948008 A NZ 59948008A NZ 599480 A NZ599480 A NZ 599480A
Authority
NZ
New Zealand
Prior art keywords
desmethylvenlafaxine
solid forms
anxiety
pain
depression
Prior art date
Application number
NZ599480A
Other languages
English (en)
Inventor
Michael Sizensky
Harold S Wilkinson
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of NZ599480A publication Critical patent/NZ599480A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NZ599480A 2007-02-21 2008-02-21 Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof NZ599480A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21
NZ579137A NZ579137A (en) 2007-02-21 2008-02-21 Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof

Publications (1)

Publication Number Publication Date
NZ599480A true NZ599480A (en) 2013-10-25

Family

ID=39432564

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ599480A NZ599480A (en) 2007-02-21 2008-02-21 Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
NZ579137A NZ579137A (en) 2007-02-21 2008-02-21 Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ579137A NZ579137A (en) 2007-02-21 2008-02-21 Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof

Country Status (18)

Country Link
US (2) US20090005457A1 (enExample)
EP (2) EP2114863B1 (enExample)
JP (1) JP5666140B2 (enExample)
KR (1) KR101528326B1 (enExample)
CN (1) CN101663263A (enExample)
AR (1) AR065431A1 (enExample)
AU (1) AU2008218997B2 (enExample)
BR (1) BRPI0807604A2 (enExample)
CA (1) CA2678599C (enExample)
ES (1) ES2609264T3 (enExample)
IL (1) IL200514A (enExample)
MX (1) MX2009008705A (enExample)
NZ (2) NZ599480A (enExample)
RU (1) RU2477269C2 (enExample)
SG (1) SG175611A1 (enExample)
TW (1) TWI446903B (enExample)
WO (1) WO2008103461A2 (enExample)
ZA (1) ZA200905698B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523662A (ja) * 2007-04-09 2010-07-15 セプラコール・インコーポレイテッド 睡眠関連呼吸障害を処置するための方法及び組成物
CZ301503B6 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ302145B6 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
CA2773948A1 (en) * 2011-04-12 2012-10-12 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
US10464873B2 (en) * 2017-02-09 2019-11-05 R L Finechem Private Limited Process for preparation of 1-[2-(dimethyl amino)-1-(4-hydroxyphenyl) ethyl]-cyclohexanol and salts thereof
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法
WO2020116963A1 (ko) 2018-12-05 2020-06-11 주식회사 헤지호그 엔도텔린 수용체 a 활성 조절 항체
MX2022014737A (es) * 2020-05-26 2023-01-04 Mars Inc Proceso para preparar alimento para mascotas y alimento para mascotas obtenible a traves del mismo.
CN116199590B (zh) * 2022-12-26 2024-12-24 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
EP1864967A1 (en) * 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
WO2003050075A1 (en) * 2001-12-05 2003-06-19 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
EP1519720A4 (en) 2002-06-10 2010-02-10 Wyeth Corp NOVEL O-DESMETHYLVENLAFAXINE FORMALITY SALT
CN101257898A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法

Also Published As

Publication number Publication date
TW200901955A (en) 2009-01-16
CA2678599A1 (en) 2008-08-28
WO2008103461A3 (en) 2008-11-13
EP2500337A2 (en) 2012-09-19
JP5666140B2 (ja) 2015-02-12
IL200514A (en) 2013-12-31
JP2010519300A (ja) 2010-06-03
AU2008218997B2 (en) 2013-06-20
CN101663263A (zh) 2010-03-03
KR101528326B1 (ko) 2015-06-11
US20090005457A1 (en) 2009-01-01
EP2114863A2 (en) 2009-11-11
RU2009135016A (ru) 2011-03-27
MX2009008705A (es) 2009-09-10
BRPI0807604A2 (pt) 2014-07-22
EP2114863B1 (en) 2016-10-05
AU2008218997A1 (en) 2008-08-28
KR20090113904A (ko) 2009-11-02
IL200514A0 (en) 2010-04-29
WO2008103461A2 (en) 2008-08-28
ES2609264T3 (es) 2017-04-19
TWI446903B (zh) 2014-08-01
US20160355457A1 (en) 2016-12-08
NZ579137A (en) 2012-05-25
CA2678599C (en) 2015-11-10
ZA200905698B (en) 2010-10-27
EP2500337A3 (en) 2012-12-26
SG175611A1 (en) 2011-11-28
AR065431A1 (es) 2009-06-10
RU2477269C2 (ru) 2013-03-10

Similar Documents

Publication Publication Date Title
NZ599480A (en) Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
EP2152318A4 (en) COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
MX2007007189A (es) Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
NZ592504A (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
EP1917065A4 (en) ADJUSTMENT MECHANISM FOR ELECTRICAL MEDICAL DEVICES AND APPLICATION METHODS
MX2010001464A (es) Polvos.
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
IL200764A0 (en) Composition comprising epha3 antibodies and use thereof for the treatment of solid tumors
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
TNSN07165A1 (en) Organic compounds
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
PT1758860E (pt) 3-piridil-benzocicloalquilmetil-aminas saturadas e insaturadas para utilização no tratamento da dor, depressões e estados de ansiedade
TW200730506A (en) Compounds and uses thereof
IL187405A0 (en) Methods and compositions for the treatment of pain
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
MY155342A (en) Antitumoral compounds
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.
JO2662B1 (en) Use of 4-methoxy-cyclopropyl-5, 3-N-dichloro-1-oxoperidine-4-yl-5 (methoxy) pyridine-2-carboxamide in the treatment of spinal cord injuries
IL201448A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of motor disorders related to parkinson's disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 FEB 2015 BY HENRY HUGHES

Effective date: 20140324

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2016 BY COMPUTER PACKAGES INC

Effective date: 20150131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2017 BY COMPUTER PACKAGES INC

Effective date: 20160202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2018 BY COMPUTER PACKAGES INC

Effective date: 20170131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2019 BY COMPUTER PACKAGES INC

Effective date: 20180131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2020 BY COMPUTER PACKAGES INC

Effective date: 20190131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2021 BY COMPUTER PACKAGES INC

Effective date: 20200131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2022 BY COMPUTER PACKAGES INC

Effective date: 20210130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2023 BY COMPUTER PACKAGES INC

Effective date: 20220130

LAPS Patent lapsed